Loading
Phone :
+1 (858) 366 - 8608
Address :
NovaRhythm Biosciences, Inc
9311 SE Maricamp Rd #1007
Ocala, FL 34472 USA
Email :
info@novarhythmbio.com

News

Novarhythm Acquires license From Sanofi

FOR IMMEDIATE RELEASE

San Diego, CA — [Month] [Day], [Year] — NovaRhythm Biosciences, a biotechnology company developing next-generation therapeutics for cardiac arrhythmias, today announced the successful in-licensing of SAR-297871, a highly selective TASK-1 potassium channel inhibitor originally developed by Sanofi for the treatment of Atrial Fibrillation (AF). Under the agreement, NovaRhythm obtains exclusive global rights to progress the molecule through IND-enabling studies and Phase 1 clinical development, with a primary objective of establishing first-in-human safety and pharmacokinetics.

SAR-297871 represents one of the most advanced precision-mechanism AF drug candidates in development today. The molecule was previously supported by extensive preclinical investment by Sanofi, including medicinal chemistry, in-vivo pharmacology, and human ex-vivo cardiac tissue validation. Data generated to date demonstrate a compelling efficacy and safety profile, with atrial-selective channel targeting designed to minimize risk of ventricular proarrhythmia, a significant limitation of existing anti-arrhythmic drugs.

 

“This agreement marks a foundational milestone for NovaRhythm,” said Paul E. Miller, PhD, CEO of NovaRhythm Biosciences. “SAR-297871 offers a novel mechanism aimed at restoring healthy cardiac rhythm and rate with fewer side effects, addressing a critical gap in the treatment landscape for millions of patients with atrial fibrillation. We are proud to continue the forward trajectory of this important asset and advance it toward first-in-human studies”.

 

Atrial Fibrillation affects more than 59 million people globally, with incidence rising as populations age. Existing drug therapies remain effective for only a subset of patients and are often limited by tolerability and safety constraints. As a next-generation mechanism directly targeting the atrial-specific TASK-1 channel, SAR-297871 seeks to overcome these therapeutic limitations and deliver improved rhythm and rate control with a more favorable risk profile.

 

A spokesperson for Sanofi added: “We are pleased to see SAR-297871 advancing into its next phase of clinical development under NovaRhythm Biosciences. NovaRhythm brings deep electrophysiology expertise and a highly focused development plan — an ideal environment for unlocking the therapeutic potential we believe this compound holds for patients living with atrial fibrillation.”

 

NovaRhythm expects to complete IND-enabling work with its established development partners and is preparing for Phase 1 initiation following regulatory clearance. The company will provide ongoing updates as the program progresses.

  

About NovaRhythm Biosciences

NovaRhythm Biosciences is a cardiovascular therapeutics company advancing first-in-class treatments for cardiac arrhythmias. The company leverages human-based disease modeling, targeted ion-channel pharmacology, and rapid-cycle translational development to bring curative rhythm-restoring therapies to patients worldwide.  NovaRhythm’s lead program, SAR-297871, is positioned to be a breakthrough therapeutic for atrial fibrillation — the most common clinically significant arrhythmia.

  

About Sanofi

Sanofi is a global healthcare leader dedicated to improving access to medicine, advancing innovative research, and supporting the health and well-being of patients around the world. With a broad global footprint and deep expertise across specialty care, vaccines, immunology, and chronic disease, Sanofi continues to deliver transformative medicines to millions of patients in over 100 countries.

  

Media Contact

NovaRhythm Biosciences Investor & Media Relations Email: info@novarhythmbio.com Phone: +1 (858) 366-8608

Website: www.novarhythmbio.com